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Background: The effects of lithium treatment on renal function have been previously shown, albeit with discrepancies
regarding their relevance. In this study, we examined glomerular filtration rate in patients treated with lithium for up to
33 years.
Methods: All lithium patients registered from 1980 to 2012 at a Lithium Clinic were screened. Estimated glomerular
filtration rate (eGFR) was calculated from serum creatinine concentration using the Modification of Diet in Renal
Disease Study Group equation. A cross-sectional evaluation of the last available eGFR of 953 patients was carried out
using multivariate regression analysis for gender, current age, and duration of lithium treatment. Survival analysis was
subsequently applied to calculate the time on lithium needed to enter the eGFR ranges 45 to 59 mL/min/1.73 m2
(G3a) or 30 to 44 mL/min/1.73 m2 (G3b). Finally, 4-year follow-up of eGFR was examined in subgroups of patients who,
after reduction to an eGFR lower than 45 mL/min/1.73 m2 either i) continued lithium at the same therapeutic range or
ii) discontinued lithium or continued at concentrations below the therapeutic range (0.5 mmol/L).
Results: In the cross-sectional evaluation, eGFR was found to be lower in women (by 3.47 mL/min/1.73 m2), in older
patients (0.73 mL/min/1.73 m2 per year of age), and in patients with longer lithium treatment (0.73 mL/min/1.73 m2
per year). Half of the patients treated for longer than 20 years had an eGFR lower than 60 mL/min/1.73 m2. The median
time on lithium taken to enter G3a or G3b was 25 years (95% CI, 23.2–26.9) and 31 years (95% CI, 26.6–35.4), respectively.
Progression of renal failure throughout the 4-year follow-up after a reduction to an eGFR lower than 45 mL/min/1.73 m2
did not differ between the subgroup who continued lithium as before and the subgroup who either discontinued
lithium or continued at concentrations below the therapeutic range.
Conclusions: Duration of lithium treatment is to be added to advancing age as a risk factor for reduced glomerular
filtration rate. However, renal dysfunction tends to appear after decades of treatment and to progress slowly and
irrespective of lithium continuation.
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Lithium is the most effective long-term therapy for bipolar
disorder [1,2] and is also effective in unipolar depression
[3]. However, some concerns have frequently been raised
about its safety [4]. In an article published in 2013 in
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nephropathy in long-term treatment [5]. These comments
were prompted by the publication of a study by our group
regarding 139 patients at different stages of lithium treat-
ment and 70 patients treated with other mood stabilizers.
Although based on a cross-sectional evaluation, data indi-
cated a positive correlation between duration of lithium
treatment and reduced estimated glomerular filtration rate
(eGFR) [6].
In the present study, we extended the cross-sectional
analysis to the entire cohort of patients registered at our
Lithium Clinic between 1980 and 2012 (n = 1,862). Weral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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duration of lithium treatment. Moreover, we introduced a
longitudinal view in order to calculate the time taken before
reduction to an eGFR lower than 60 mL/min/1.73 m2 while
on lithium and to follow the progression of renal failure in
case of continuation or discontinuation of lithium.
Methods
All lithium patients registered between January 1, 1980,
and December 31, 2012, at the Unit of Clinical Pharma-
cology, University Hospital of Cagliari, were screened.
The study protocol was approved by the local Ethics
Committee of the University Hospital of Cagliari, Italy
(reference number 16/09/CE). All patients gave written
informed consent before inclusion in the study. The
study was performed in accordance with the Declaration
of Helsinki.
To ascertain actual exposure to lithium, duration of
treatment was calculated for each patient by adding up
the years during which lithium was regularly found
within the therapeutic range (0.5 to 1.0 mmol/L) and for
whom the interval between checks on serum lithium
concentrations at our Unit did not exceed four months.
Serum creatinine concentrations were taken from the
panel of laboratory tests requested on an annual basis.
The traditional standardization method for serum cre-
atinine was used. The eGFR was calculated from serum
creatinine values using the equation proposed by the
Modification of Diet in Renal Disease Study Group [7,8],
with the ‘186’ correction factor, which also takes into ac-
count age, sex, and ethnicity. The following categories of
eGFR were considered: higher than 90 mL/min/1.73 m2
(G1); 60 to 89 mL/min/1.73 m2 (G2); 45 to 59 mL/min/
1.73 m2 (G3a); 30 to 44 mL/min/1.73 m2 (G3b); 15 to
29 mL/min/1.73 m2 (G4); and lower than 15 mL/min/
1.73 m2 (G5). The abbreviations and ranges recall those
used by the Kidney Disease Improving Global Outcomes
2012 Clinical Practice Guidelines for the Evaluation and
Management of Chronic Kidney Disease (CKD) [9], but
it must be noted that these stages are also based on
albuminuria categories, which were not included in the
present study. To avoid misclassification based on single
eGFR determinations, a best-estimate was established
based on the last two available values. When the last two
eGFR values oscillated between two contiguous ranges,
the patient was assigned to intermediate categories (for
example G1/G2 or G2/G3a).
To corroborate the results from our previous cross-
sectional study regarding a subsample of 139 lithium
patients [6], multivariate regression analysis was applied
to cross-sectional data regarding the entire cohort of
patients. In this case, the last available eGFR was included
as the dependent variable. The independent variables were
age, sex, and duration of lithium treatment.Survival analysis was applied to estimate the number
of years on lithium required to enter the eGFR ranges
45 to 59 mL/min/1.73 m2 (G3a) or 30 to 44 mL/min/
1.73 m2 (G3b). The median time to reach the different
eGFR stages was calculated, in the whole sample, using
the Kaplan-Meier method. According to this method, in
cases when the stage under consideration had not been
reached, data were censored at the last follow-up visit.
Kaplan-Meier curves were generated for the entire sam-
ple or after stratification into age groups. In the latter
case, the log rank test was applied to compare survival
distributions. Cox proportional hazards regression was
applied to control for age and sex.
The progression of renal failure after a reduction to an
eGFR lower than 45 mL/min/1.73 m2 was studied in the
following two subgroups: i) patients who continued lith-
ium at the same therapeutic range and ii) patients who
either discontinued lithium or continued at concentra-
tions below the therapeutic range (0.5 mmol/L). The latter
subgroup was combined to allow an adequate sample size,
as patients tended to be lost to follow-up at the lithium
clinic. Parametric and non-parametric tests were used to
compare eGFR values between the two subgroups and
between different follow-up intervals.
Results
Of 1,862 patients in the lithium register, 953 (596 females,
357 males) met the following criteria and were studied: i)
having been treated at the lithium clinic for at least one
year and ii) having at least one serum creatinine value
available to calculate eGFR.
Cross-sectional data
Figure 1 and Table 1 show the results from multivariate
analysis of the last available eGFR of the 953 patients
studied. The results can be summarized as follows: eGFR
was lower in women (by 3.47 mL/min/1.73 m2), in older
patients (0.73 mL/min/1.73 m2 per year of age), and in
patients with longer lithium treatment (0.73 mL/min/
1.73 m2 for each year).
Figure 2 shows the proportion of patients falling into
various categories of eGFR among subgroups exposed to
lithium for different times, just to provide a view of the
relevance of reduced eGFR. In this case, the last two
available eGFR values were used for cross-sectional evalu-
ation of the current eGFR range to avoid misclassification
based on single eGFR determinations.
Although the effect of age is not included, Figure 2
provides a perspective on critical cases. For example, it is
noteworthy that, irrespective of age, half of the patients
treated with lithium for longer than 20 years had an eGFR
lower than 60 mL/min/1.73 m2, which usually recom-
mends consultation with a nephrologist, whereas 40% of
patients treated for longer than 25 years had an eGFR
Figure 1 Last available estimated glomerular filtration rate by
current age and duration of lithium treatment in 953 patients.
Table 1 Multivariate analysis of the last available
estimated glomerular filtration rate in 953 patients
treated with lithium for up to 33 years
Variable Beta P value 95% confidence
interval
Gender (male versus female) 3.47 0.008 0.91 6.02
Current age –0.73 3.0 × 10–56 –0.82 –0.65
Duration of lithium treatment –0.73 1.8 × 10–14 –0.91 –0.55
Figure 2 Prevalence of patients falling into different estimated
glomerular filtration rate (eGFR) categories among subgroups
exposed to lithium for different times. The last two available
eGFR values were used to assign patients to the following eGFR
categories: G1, both values higher than 89 mL/min/1.73 m2; G1/G2,
one value within G1 and one within G2; G2, both values between 60
and 89 mL/min/1.73 m2; G2/G3a, one value within G2 and one
within G3a; G3a, both values between 45 and 59 mL/min/1.73 m2;
G3b–G5, both values lower than 44 mL/min/1.73 m2.
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a point of no return.
Longitudinal data
Figures 3 and 4 show the Kaplan-Meier curves regarding
the entire sample. Of the 953 patients studied, 136
declined to an eGFR lower than 60 mL/min/1.73 m2 and
68 to an eGFR lower than 45 mL/min/1.73 m2; the median
time taken was 25 years (95% confidence interval (CI),
23.2–26.9) and 31 years (95% CI, 26.6–35.4), respectively.
The median time taken to decline from range G3a to G3b
was 8 years (95% CI, 6.6–9.4).
Stratification into age subgroups (data not shown)
revealed no differences regarding the time required to
enter the G3b range, whereas the time to enter the G3a
range differed significantly (overall log rank test,15.4;
P <0.0001). In this case, median time was not reached
and could not be calculated in the age subgroup youn-
ger than 40 years, whereas it was shorter in the age
subgroup ≥60 years (23 years; 95% CI, 19.7–26.3) as
compared to the age subgroup 40–59 years (26 years;
95% CI, 24.5–27.5).
Cox regression revealed the following age and sex effects:
i) the hazard ratio (HR) to enter range G3a increased with
age (HR, 1.03; 95% CI, 1.02–1.05); ii) men had a lower risk
of entering range G3b as compared to women (HR, 0.49;
95% CI, 0.25–0.96).
Table 2 shows the outcome in the subgroups of patients
who had a reduction in eGFR to lower than 45 mL/min/
1.73 m2 (set as time zero) and i) continued lithium at the
usual therapeutic concentration range (0.50 to 1.0 mmol/
L) or ii) either discontinued lithium or continued at con-
centrations below the therapeutic range (0.5 mmol/L).
Figure 3 Kaplan-Meier curve showing years on lithium treatment taken to enter stage G3a (45 to 59 mL/min/1.73 m2; 136 events out
of 953 patients; 1- to 33-year follow-up).
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with regard to mean eGFR at time zero. No significant
between-group differences were evident in eGFR up to
4-year follow-up. The median decline in eGFR did not
differ from one subgroup to another (P = 0.305 at Mann-
Whitney U test).
Discussion
Our results corroborate previous findings indicating that
the duration of lithium treatment must be added toFigure 4 Kaplan-Meier curve showing years on lithium treatment take
953 patients; 1- to 33-year follow-up).advancing age as a risk factor for reduced renal function
in patients with recurrent or chronic affective illness.
The longitudinal part of this study, including a large
cohort of patients treated at a specialized facility for up
to 33 years, provides suggestions that can help clinicians
make decisions regarding long-term lithium treatment.
In the cross-sectional multivariate analysis of the last
eGFR from the entire sample, we found that older
patients had lower values (0.73 mL/min/1.73 m2 per year
of age). This result is consistent with the eGFR declinen to enter stage G3b (30 to 44 mL/min/1.73 m2; 68 events out of
Table 2 Follow-up of estimated glomerular filtration (eGFR) in subgroups of patients with a diagnosis of renal failure,
continuing lithium treatment as before or discontinuing/reducing lithium intake
Follow-up interval
after the diagnosis of
renal failure (years)
Patients who continued lithium as before Patients who discontinued or reduced lithium below
the therapeutic range
Mean eGFR n Mean eGFR n
0 39.3 54 37.6 45
1 41.1 39 39.5 28
2 38.6 30 37.9 23
3 36.7 22 33.8 18
4 36.2 24 32.1 15
There were no significant differences between subgroups or between year 1 to 4 and year zero (unpaired tests).
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population from a Sardinian region (0.79 mL/min/1.73 m2
per year over an average seven-year follow-up) [10].
The cross-sectional analysis from this study revealed
that, after age and sex corrections, there is an additional
negative effect of the duration of lithium treatment
(0.73 mL/min/1.73 m2 per year of treatment). Therefore,
we can estimate that long-term lithium exposure to
therapeutic concentrations may double the eGFR decline
associated with advancing age.
However, according to our longitudinal evaluation, it
appears that it may take decades before patients fall into
severely reduced eGFR ranges. This is perhaps one of
the principal reasons why early studies with limited
follow-up had not pointed out the relevance of reduced
glomerular function in lithium-treated patients. Indeed,
a recent systematic review and meta-analysis of lithium
toxicity profile concluded that “there is little evidence for
a clinically significant reduction in renal function in
most patients, and the risk of end-stage renal failure is
low” [4]; the conclusions, however, were based on pro-
spective studies with a mean observation time of one year
on lithium. Further, the meta-analysis does not include
data from naturalistic studies conducted under ordinary
clinical conditions and is not equipped to assess the
epidemiological relevance of lithium-related renal impair-
ment, as stated by Müller-Oerlinghausen et al. in BMC
Medicine [11].
Nevertheless, adverse renal effects of lithium have long
been known, varying from very frequent reversible poly-
uria [12] to irreversible kidney damage [13,14]. Early
studies reported tubular damage but no (or minimal)
glomerular damage (for a review, see [15]). Analysis of
studies published from 1979 to 1986 comprising 1,172
patients concluded that glomerular filtration rate was
normal in 85% of unselected patients on chronic lithium
therapy and that the remaining 15% of patients displayed
only a mild reduction in glomerular filtration rate, clus-
tering at approximately 60 mL/min [16]. A more recent
study by Tredjet et al. [17] reported a prevalence of
34.4% with lower than 60 mL/min /1.73 m2 [17]. Up tothe 1990’s, severe renal failure and end-stage renal disease
(ESRD) were considered unlikely events [18]. Subsequent
studies principally originated from nephrology facilities
and focused on the small number of extremely severe
cases [19-21]. For example, Markowitz et al. [19] studied
24 patients with renal biopsy and concluded that: i) lith-
ium may be responsible for combined glomerular and
tubular-interstitial damage; ii) toxicity may be irreversible,
even despite lithium withdrawal; and iii) early detection is
essential to prevent progression to ESRD. Our results are
comparable to those from Presne et al. [20] who, based on
data from 74 patients, concluded that lithium-induced
CKD progresses slowly, its rate of progression related to
the duration of exposure. Bendz et al. [21] described 32
cases in Sweden of ESRD associated with long-term
lithium exposure, underscoring the potential role of the
relatively higher therapeutic ranges adopted in the 1960
to 1970’s as compared to current guidelines. This may
not be the case with our lithium cohort, dating no further
back than 1980 and maintained within a therapeutic range
between 0.5 and 1.0 mmol/L. We have planned to investi-
gate the effect of lithium concentration in another account.
The lack of large surveys has recently prompted studies
addressing the epidemiological relevance of less severe
CKD stages, compared to studies from nephrology facilities.
An advance in epidemiological surveys of large populations
was represented by the demonstrated reliability of eGFR
calculated from routine laboratory determinations of serum
creatinine [7,8]. Previous studies of renal dysfunction in
lithium patients had often relied on serum creatinine values
alone, setting the alarm signal at 140 mmol/L (1.6 mg/dL),
which might have resulted in an underestimated prevalence
of renal failure, especially among older patients [18].
More recent studies using eGFR changed the perspec-
tive. For example, Bassilios et al. [22] found a very high
prevalence of eGFR lower than 60 mL/min/1.73 m2
among 695 outpatients referred to their private laboratory
in Paris for measurement of lithium serum concentra-
tions. Reduced eGFR was especially prevalent in older age
groups (78 to 86% of patients older than 60 years had an
eGFR lower than 60 mL/min/1.73 m2), consistent with the
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study, theirs did not analyze duration of lithium treat-
ment, and the majority of patients were no longer being
treated at specialized lithium clinics [22]. As stated by
Müller-Oerlinghausen et al. [11], “regular kidney function
monitoring is often lacking in practice”, and the “French
study shockingly showed that creatinine serum levels had
not been performed in 40%” of lithium patients referred
to their laboratory; the comment also underlined that,
unfortunately, the risk of renal dysfunction “might not
be that rare, even in subjects properly managed on lith-
ium”. Prevalence rates were somehow lower among
patients from our cohort who were regularly treated at
a lithium clinic as compared to those from the French
survey, but, in any case, rates can be considered im-
pressive as compared to the 15% prevalence calculated
by the review of earlier studies of unselected patients
on chronic lithium [16].
In the debate regarding the epidemiological relevance
of renal dysfunction among lithium-treated patients, our
results can be added to those from another recent retro-
spective cohort study examining the risk of renal impair-
ment (CKD stage 3) or failure (CKD stages 4 or 5) among
6,360 patients with bipolar disorder, treated or not with
lithium and recorded from 1990 to 2007 in the UK
General Practice Research Database [23]. In that UK study,
lithium use (defined as at least one prescription of at least
30 days duration) was associated with a HR for renal failure
of 2.5 and a HR for renal impairment of 2.7. Risk particu-
larly increased among the 50-or-older age group.
The principal results from both the UK study and our
own are similar. One advantage of our study is that lithium
exposure was checked with regular serum monitoring.
Moreover, duration of treatment and actual eGFR measure-
ments were included in our analysis and we were able to
longitudinally describe the relatively slow eGFR decline.
On the other hand, our study has obvious limitations.
For example, we have not explored the role of known
renal risk factors (diabetes, hypertension, use of NSAIDs,
smoking, etc.), and there was no comparison with a group
of patients suffering from recurrent mood disorder but
not exposed to lithium.
We maintain that naturalistic studies from lithium
clinics may be relevant with regard to the risk of renal
failure. As stated by Müller-Oerlinghausen et al. [11],
“when to discontinue lithium because of serious renal
problems is a particularly vexing problem. This decision
cannot be made solely by the treating nephrologist, but
also requires expert psychiatric evaluation of the benefits
and true risks that the individual patient can expect
from his/her lithium medication in future years”. Indeed,
the benefits obtained from lithium must be regarded not
only in terms of stabilization of recurrent mood disorders,
but also in normalization of their otherwise increasedmortality, mainly due to suicide [24-26]. Werneke et al.
[27] conducted a decision analysis simulating the decision
process between physicians and patients. The analysis
addressed two questions: ‘Should lithium be recom-
mended at the beginning of treatment in view of a small
but significant risk of ESRD later in life?’ and ‘Should lith-
ium continuation be recommended even in the presence
of long-term adverse renal effects?’
Surprisingly, guidelines regarding such important ques-
tions are often based on limited literature data – the aim
of this study was to aid in filling this gap. To our know-
ledge, this is the first attempt to actually estimate the time
needed to enter the eGFR ranges generally considered
crucial in the management of lithium treatment. With
regard to the outcome of renal failure in lithium-treated
patients, data from the literature are particularly scarce
and controversial. A few studies suggest that advanced
stages of renal failure appear to progress irrespective of
the continuation or discontinuation of lithium treatment,
while others suggest that discontinuation may be beneficial
[19-21,28]. Our follow-up data add a small contribution to
the debate, suggesting that the reduction in eGFR is slow,
even after falling into eGFR values lower than 45 mL/min/
1.73 m2 and irrespective of lithium discontinuation or
reduction below the usual therapeutic range.
Opting for discontinuation must be cautious consider-
ing previous evidence that mortality may be dispropor-
tionally high in patients with irregular attendance at our
lithium clinic. For example, 43 suicides were recorded
from 1980 to 2002 among patients in our lithium register:
42 of 43 were not under regular lithium prophylaxis; on
the other hand, renal failure was recorded as the main
cause of death in only two cases [26].Conclusions
These results confirm that reduction in renal function,
even if rarely progressing to end-stage renal failure,
should be reconsidered in the debate on the lithium
toxicity profile. Duration of lithium treatment is to be
added to advancing age as a risk factor. However, the
risk of renal dysfunction must be weighed against the
protective effects of lithium on the recurrence of mood
disorders, quality of life, and suicide. As continuation or
discontinuation of lithium does not appear to significantly
influence the progression to ESRD once kidneys are
already damaged, it would be desirable that future studies
identify early markers of lithium nephrotoxicity.
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